Kimberly is a leading voice in the patent agent community. She has a PhD in chemistry and currently serves on the Canadian Patent Agent Examining Board for the qualification of Canadian Patent Agents. Kimberly thrives on the challenge of figuring out how best to claim, strengthen and protect her clients’ inventions to create a strategic patent portfolio.
Kimberly is a registered Patent Agent in Canada and the United States. The focus of her practice is on drafting and prosecuting patent and design applications, preparing patentability, infringement, validity and freedom-to-operate opinions, providing worldwide strategic patent and design portfolio management and conducting due diligence in patent and design valuations.
Kimberly specializes in the areas of chemistry, pharmaceutics, medical devices, aerospace and energy and mining. More specifically, she specializes in the fields of organic and inorganic chemistry, such as pharmaceutical formulations, polymers, surfactants, petroleum, propellants, electrochemistry, photochemistry and synthesis. Kimberly’s post-doctoral research experience in chemistry related to synthesis of new drugs for photodynamic therapeutic treatment of cancer (Queen Mary and Westfield College, London, England) and the development of new polymeric materials and methodologies for holographic data storage (NSF Center for Photoinduced Charge Transfer, University of Rochester, Rochester, NY). During that time she co-authored several well-known scientific publications.
Kimberly is a Fellow of the Intellectual Property Institute of Canada (IPIC) and a member of the American Chemical Society (ACS), Chemical Institute of Canada (CIC), the Intellectual Property Owners Association (IPO), the American Intellectual Property Law Association (AIPLA) and the Association of University Technology Managers (AUTM). In addition to serving on the Canadian Patent Agent Examining Board, she currently serves on the Women’s IPO Committee and the Canadian Practice IPO Committee.
Her clients include academic/research institutes, start-up companies, pharmaceutical small and medium-sized enterprises (SMEs) and larger blue chip companies.
